Clinical Pharmacology & Biopharmaceutics
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Hepatotoxicity is one of the major adverse effects of Anti tuberculosis (Anti-TB) drugs. Retrospective cohort study was conducted
to evaluate prevalence and risk factors associated Anti-TB drug induced hepatitis in four states of Malaysia from January 2006
to December 2007. TB patients with human immunodeficiency virus and incomplete medical record were excluded. A purpose
developed valid data collection form was used for collecting demographic and clinical data. Data was analyzed by using SPSS 16?.
Of 8277 patients, 322 (3.9%) patients of the studied population developed drug induced hepatitis. In Univariate analysis, gender
(p=0.021), diabetes mellitus (p<0.001), alcohol consumption (p<0.001), intravenous drug users (p<0.001), patients of weight, 31-
50 Kg (p=0.038), 51-70 Kg (p=0.001) and belonging to Pulau Pinang (p<0.001) and Sarawak (p<0.001) states had statistically
significant association with drug induced hepatitis. In multivariate analysis diabetes mellitus (OR=0.516, p<0.001) and Sarawak
state (OR=0.615, p=0.005) had significant negative association, while intravenous drug users (OR=4.126, p-value<0.001), patients
belonging to weight group (51-70 Kg) (OR=1.875, p=0.020) and Pulau Pinang state (OR=1.806, p<0.001) had statistically positive
association with drug induced hepatitis. This model fit was based on a non-significant Hosmer and Lemeshow test (p= 0.289).
The prevalence of drug induced hepatitis was 3.9%. Intravenous drug users, patients belonging to Pulau Pinang state and falling
in weight group of 51-70 Kg were the risk factors associated with drug induced hepatitis. Doctors caring for these high risk groups
patients should be aware of the increased prevalence of drug induced hepatitis in their patients.
Amer Hayat Khan completed Ph.D. in Clinical Pharmacy from Universiti Sains Malaysia, in 2010. Currently he is working as Senior Lecturer in
Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia. Communicable diseases and surgical infections are
the main focus of research of Dr. Amer, and currently supervising 2 Ph.D.?s and 6 Master research fellows. He has published more than 38 papers
in reputable journals and serving as an editorial board member of Journal.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals